MDXG Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
64.4M
+9.1%
59.0M
-50.0%
118.1M
+3.8%
113.7M
+15.3%
98.6M
Cost of Revenue
20.0M
+15.0%
17.4M
-8.9%
19.1M
+1.8%
18.7M
+0.2%
18.7M
Gross Profit
44.4M
+6.6%
41.6M
-58.0%
99.0M
+4.2%
95.0M
+18.9%
79.9M
Operating Expenses
62.8M
+9.0%
57.7M
-26.0%
78.0M
+7.1%
72.8M
+7.8%
67.6M
R&D
2.8M
-32.9%
4.1M
-13.0%
4.8M
+28.6%
3.7M
+12.1%
3.3M
SG&A
59.8M
+12.3%
53.2M
-27.2%
73.1M
+5.9%
69.0M
+7.6%
64.2M
Operating Income
-18466000
-15.1%
-16049000
-176.1%
21.1M
-5.0%
22.2M
+79.4%
12.4M
EBITDA
-16935000
-17.3%
-14432000
-159.4%
24.3M
-11.6%
27.5M
+76.9%
15.5M
Net Income
-14840000
-36.6%
-10860000
-171.5%
15.2M
-9.3%
16.7M
+74.1%
9.6M
EPS (Basic)
$-0.10
-42.9%
$-0.07
-170.0%
$0.10
-9.1%
$0.11
+57.1%
$0.07
EPS (Diluted)
$-0.10
$0.00
-100.0%
$0.10
-9.1%
$0.11
+83.3%
$0.06
Shares (Diluted)
147.8M
-0.4%
148.4M
-1.2%
150.2M
+0.3%
149.7M
+0.3%
149.3M
MiMedx (MDXG) โ€” Financials